Navigation Links
Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
Date:4/22/2008

ith Anthim has the potential to provide 'instant protective immunity' against the anthrax toxin in a bioterrorism emergency. We believe Anthim represents an extremely important medical countermeasure for the treatment of anthrax and should be added to the National Stockpile."

Currently antibiotics represent the only option for the treatment of anthrax infection. Antibiotics may be effective in killing the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, current antibiotics may not be effective at all against antibiotic resistant strains of anthrax.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. Elusys has been awarded $32 million from the National Institutes of Health and the Department of Defense for development of Anthim, of which $12 million was awarded in September 2007 from the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services for advanced development of Anthim. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs."

About Elusys

Based in Pine Brook, New Jersey, venture-backed Elusys has two corporate partnerships with MedImmune and Pfizer for development of its HP Antibodies targeting select infectious diseases. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ve
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
2. Special coating greatly improves solar cell performance
3. Method to deliver molecules within embryonic stem cells improves differentiation
4. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
5. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
8. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
9. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Personal Genome Diagnostics ... its proprietary methodologies and expertise in genomic analysis ... targets in collaboration with Blueprint Medicines.  PGDx is ... identifying genomic alterations in tumors, and Blueprint Medicines ... inhibitors for a genetically defined patient population. ...
(Date:5/21/2013)... MN (PRWEB) May 21, 2013 Revolutionary ... patented automatic colony counter, announced today that they have ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... and sophistication are especially useful in food microbiology and ... given an updated look. A bright white enclosure ...
(Date:5/21/2013)... Ontario (PRWEB) May 21, 2013 ... scientists of the ITN to design the study, ... of two key clinical models used in the ... (EEC) and Nasal Allergen Challenge (NAC) models. Although ... by numerous publications, to date no direct comparison ...
(Date:5/21/2013)... 2013 Possible mold re-infestation in Guilemtte School ... a report from eagletribune.com posted May 14, 2013, the state ... result is positive, My Cleaning Products offered a tip ... , It was said in the Eagle Tribune report (5.14.13) ... campus sparked after a first-grade classroom was closed due to ...
Breaking Biology Technology:Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3
... Ill., May 3, 2011 Landauer, Inc. (NYSE: ... and environmental radiation monitoring and the leading domestic provider of ... fiscal 2011 second quarter ended March 31, 2011.   ... grew 2 percent to $32.3 million on contribution from Medical ...
... Answering the need for global, site-focused enrollment support, ... enrollment industry, announces the expansion of its services to ... site-centric level. "The extension of our worldwide ... to assist sponsors with their global patient enrollment needs," ...
... Corporation (NASDAQ: TECH ) (Techne) announced today ... Limited and subsidiaries (Tocris), a leading supplier of reagents ... in both in-vitro and in-vivo experiments, to understand biological ... biologically active neuro- and bio-chemicals which are used by ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4Techne Corporation Announces Acquisition 5
(Date:5/20/2013)... of Minnesota Medical School researchers from the Masonic Cancer ... Brain Tumor Program, have developed a new mouse model ... them to discover new genes and gene pathways driving ... this week in the journal Nature Genetics . ... the lab of David Largaespada, Ph.D., professor in the ...
(Date:5/20/2013)... COLUMBUS, Ohio New research suggests that a compound ... "superpower" to escape death. , By altering a ... re-educates cancer cells into normal cells that die as ... by inhibiting a process that would cause them to ... strict programming. This study in cells, led by Ohio ...
(Date:5/20/2013)... conducted at the University of Bristol and published online ... sheds light on how the brain and inner ear ... School of Earth Sciences, together with Tom Hbner from ... of 150 million year old dinosaurs. , The two ... Dysalotosaurus lettowvorbecki : a very young (juvenile) individual ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Fossil brain teaser 2
... invites you to attend its first workshop on male ... clinical practice". The workshop provides a forum ... discuss new developments. Here some of the ... outside of Europe will announce: Nature ...
... ,The American Association of Pharmaceutical Scientists (AAPS) is ... employed in industry, academia, government and other research ... dynamic international forum for the exchange of knowledge ... health. AAPS offers timely scientific programs, on-going education, ...
... 2009 / b3c newswire / - PlatformQ , ... the healthcare, education and energy markets, and LabRoots ... scientific community, today announced the initial slate of speakers ... is the first of its kind online-only conference for ...
Cached Biology News:AAPS and PhRMA co-sponsor stability workshop 2BioConference Live Attracts Major Life Science Sponsors 2BioConference Live Attracts Major Life Science Sponsors 3